Goat anti-Mouse IgG F (ab') 2 Fragment

<strong>Goat anti-Mouse IgG F(ab')2 Fragment</strong>_x000D_ <strong>Catalog number:</strong> B2010254_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 0.250 mL_x000D_ <strong>pH:</strong> 7.4_x000D_ <strong>Supplied as:</strong> Ready-to-use_x000D_ <strong>Appearance:</strong> Solution_x000D_ <strong>Applications:</strong> high purity unconjugated IgG F(ab')2 Fragment specific to Fab. This product is suitable for many immuno-applications such as ELISA._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> anti-IgG antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered on a 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Bush SP, Ruha AM, Seifert SA, Morgan DL, Lewis BJ, Arnold TC, Clark RF, Meggs_x000D_ WJ, Toschlog EA, Borron SW, Figge GR, Sollee DR, Shirazi FM, Wolk R, de Chazal_x000D_ I, Quan D, Garc√≠a-Ubbelohde W, Alag√≥n A, Gerkin RD, Boyer LV. Comparison of_x000D_ F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded,_x000D_ multicenter, randomized clinical trial. Clin Toxicol (Phila). 2015_x000D_ Jan;53(1):37-45._x000D_ _x000D_ 2: Bellaye PS, Moreau M, Raguin O, Oudot A, Bernhard C, Vrigneaud JM, Dumont L,_x000D_ Vandroux D, Denat F, Cochet A, Brunotte F, Collin B. Radiolabeled_x000D_ F(ab')₂-cetuximab for theranostic purposes in colorectal and skin_x000D_ tumor-bearing mice models. Clin Transl Oncol. 2018 Dec;20(12):1557-1570._x000D_ _x000D_ 3: Rosenstein S, Vaisman-Mentesh A, Levy L, Kigel A, Dror Y, Wine Y. Production_x000D_ of F(ab')₂ from Monoclonal and Polyclonal Antibodies. Curr Protoc Mol_x000D_ Biol. 2020 Jun;131(1):e119._x000D_ _x000D_ 4: Valedkarimi Z, Nasiri H, Aghebati-Maleki L, Abdolalizadeh J, Esparvarinha M,_x000D_ Majidi J. Production and characterization of anti-human IgG F(ab')2 antibody_x000D_ fragment. Hum Antibodies. 2018;26(4):171-176._x000D_ _x000D_ 5: Cui Z, Li D, Yi S, Guo Y, Dong G, Niu J, Zhao H, Zhang Y, Zhang S, Cao L,_x000D_ Wang K, Zhao Y, Hu G. Equine immunoglobulin F(ab')₂ fragments protect_x000D_ cats against feline calicivirus infection. Int Immunopharmacol. 2019_x000D_ Oct;75:105714._x000D_ _x000D_ 6: Li Q, Peterson N, Hanna RN, Kuszpit K, White J, Allen KL, Barnes A, Rickert_x000D_ KW, Shan L, Wu H, Dall'Acqua WF, Tsui P, Borrok MJ. Antibody Fragment_x000D_ F(ab')₂ Targeting Caveolae-Associated Protein PV1 for Selective_x000D_ Kidney Targeting and Retention. Mol Pharm. 2020 Feb 3;17(2):507-516._x000D_ _x000D_ 7: Squaiella-Baptist√£o CC, Magnoli FC, Marcelino JR, Sant'Anna OA, Tambourgi DV._x000D_ Quality of horse F(ab')₂ antitoxins and anti-rabies immunoglobulins:_x000D_ protein content and anticomplementary activity. J Venom Anim Toxins Incl Trop_x000D_ Dis. 2018 Jun 18;24:16._x000D_ _x000D_ 8: Reveneau E, Cottin P, Rasuli A. Two decades of pharmacovigilance and clinical_x000D_ experience with highly purified rabies immunoglobulin F(ab')₂_x000D_ fragments. Expert Rev Vaccines. 2017 Mar;16(3):273-287._x000D_ _x000D_ 9: Lasoff DR, Ruha AM, Curry SC, Koh C, Clark RF. A new F(ab')₂_x000D_ antivenom for the treatment of crotaline envenomation in children. Am J Emerg_x000D_ Med. 2016 Oct;34(10):2003-2006._x000D_ _x000D_ 10: Canul-Caamal MA, Madrigal-Anaya JDC, Pastelin-Palacios R, Escalante-Galindo_x000D_ P, Moreno-Eutimio MA. Cryotherapy as a coadjuvant in crotaline snakebite_x000D_ management with F(ab')₂ antivenom: A randomized pilot study. <a href="https://pubmed.ncbi.nlm.nih.gov/33183672/">Complement Ther Med</a>. 2020 Nov;54:102569._x000D_ _x000D_ <strong>Products Related to Goat anti-Mouse IgG F(ab')2 Fragment</strong>: <a href="https://moleculardepot.com/product-category/antibodies/">Antibodies</a>